nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—Labetalol—Formoterol—chronic obstructive pulmonary disease	0.395	0.5	CrCrCtD
Lisdexamfetamine—Labetalol—Arformoterol—chronic obstructive pulmonary disease	0.395	0.5	CrCrCtD
Lisdexamfetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—CHRNA5—chronic obstructive pulmonary disease	0.00153	0.117	CbGpPWpGaD
Lisdexamfetamine—Lisinopril—ACE—chronic obstructive pulmonary disease	0.0015	0.362	CrCbGaD
Lisdexamfetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—CHRNA3—chronic obstructive pulmonary disease	0.00124	0.0955	CbGpPWpGaD
Lisdexamfetamine—Labetalol—ADRB2—chronic obstructive pulmonary disease	0.000989	0.24	CrCbGaD
Lisdexamfetamine—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.000777	0.00403	CcSEcCtD
Lisdexamfetamine—Palpitations—Tiotropium—chronic obstructive pulmonary disease	0.000773	0.00401	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.000757	0.00392	CcSEcCtD
Lisdexamfetamine—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.000755	0.00391	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.000753	0.0039	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.000753	0.0039	CcSEcCtD
Lisdexamfetamine—Euphoric mood—Prednisolone—chronic obstructive pulmonary disease	0.000751	0.00389	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Montelukast—chronic obstructive pulmonary disease	0.000751	0.00389	CcSEcCtD
Lisdexamfetamine—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000751	0.00389	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000742	0.00385	CcSEcCtD
Lisdexamfetamine—ADRA1B—Adrenoceptors—ADRB2—chronic obstructive pulmonary disease	0.000742	0.057	CbGpPWpGaD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00074	0.00383	CcSEcCtD
Lisdexamfetamine—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.000739	0.00383	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.000737	0.00382	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000732	0.0038	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.000732	0.0038	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000731	0.00379	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000731	0.00379	CcSEcCtD
Lisdexamfetamine—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000728	0.00377	CcSEcCtD
Lisdexamfetamine—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000722	0.00374	CcSEcCtD
Lisdexamfetamine—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.000722	0.00374	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.000717	0.00372	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000716	0.00371	CcSEcCtD
Lisdexamfetamine—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000716	0.00371	CcSEcCtD
Lisdexamfetamine—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000715	0.00371	CcSEcCtD
Lisdexamfetamine—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000711	0.00369	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000711	0.00368	CcSEcCtD
Lisdexamfetamine—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.00071	0.00368	CcSEcCtD
Lisdexamfetamine—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.00071	0.00368	CcSEcCtD
Lisdexamfetamine—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.000706	0.00366	CcSEcCtD
Lisdexamfetamine—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.000706	0.00366	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.0007	0.00363	CcSEcCtD
Lisdexamfetamine—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000697	0.00361	CcSEcCtD
Lisdexamfetamine—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.000696	0.00361	CcSEcCtD
Lisdexamfetamine—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000693	0.00359	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000692	0.00358	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00069	0.00358	CcSEcCtD
Lisdexamfetamine—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.000686	0.00355	CcSEcCtD
Lisdexamfetamine—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.000686	0.00355	CcSEcCtD
Lisdexamfetamine—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000685	0.00355	CcSEcCtD
Lisdexamfetamine—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000674	0.00349	CcSEcCtD
Lisdexamfetamine—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000671	0.00348	CcSEcCtD
Lisdexamfetamine—Visual disturbance—Prednisolone—chronic obstructive pulmonary disease	0.00067	0.00347	CcSEcCtD
Lisdexamfetamine—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000667	0.00345	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000666	0.00345	CcSEcCtD
Lisdexamfetamine—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000661	0.00343	CcSEcCtD
Lisdexamfetamine—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000661	0.00343	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000658	0.00341	CcSEcCtD
Lisdexamfetamine—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000649	0.00336	CcSEcCtD
Lisdexamfetamine—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000649	0.00336	CcSEcCtD
Lisdexamfetamine—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000648	0.00336	CcSEcCtD
Lisdexamfetamine—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000647	0.00336	CcSEcCtD
Lisdexamfetamine—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000646	0.00335	CcSEcCtD
Lisdexamfetamine—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000645	0.00334	CcSEcCtD
Lisdexamfetamine—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000645	0.00334	CcSEcCtD
Lisdexamfetamine—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000635	0.00329	CcSEcCtD
Lisdexamfetamine—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000632	0.00327	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000628	0.00326	CcSEcCtD
Lisdexamfetamine—Affect lability—Prednisolone—chronic obstructive pulmonary disease	0.000625	0.00324	CcSEcCtD
Lisdexamfetamine—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000625	0.00324	CcSEcCtD
Lisdexamfetamine—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000624	0.00323	CcSEcCtD
Lisdexamfetamine—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000624	0.00323	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000616	0.00319	CcSEcCtD
Lisdexamfetamine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000613	0.00317	CcSEcCtD
Lisdexamfetamine—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000611	0.00317	CcSEcCtD
Lisdexamfetamine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00061	0.00316	CcSEcCtD
Lisdexamfetamine—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000609	0.00316	CcSEcCtD
Lisdexamfetamine—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000609	0.00316	CcSEcCtD
Lisdexamfetamine—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000609	0.00316	CcSEcCtD
Lisdexamfetamine—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000601	0.00312	CcSEcCtD
Lisdexamfetamine—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000599	0.00311	CcSEcCtD
Lisdexamfetamine—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000599	0.0031	CcSEcCtD
Lisdexamfetamine—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000599	0.0031	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000598	0.0031	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000597	0.00309	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000597	0.00309	CcSEcCtD
Lisdexamfetamine—Selegiline—CYP1A2—chronic obstructive pulmonary disease	0.000595	0.144	CrCbGaD
Lisdexamfetamine—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000589	0.00305	CcSEcCtD
Lisdexamfetamine—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000588	0.00305	CcSEcCtD
Lisdexamfetamine—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000588	0.00305	CcSEcCtD
Lisdexamfetamine—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000587	0.00304	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000585	0.00303	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000576	0.00299	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000576	0.00299	CcSEcCtD
Lisdexamfetamine—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000575	0.00298	CcSEcCtD
Lisdexamfetamine—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000567	0.00294	CcSEcCtD
Lisdexamfetamine—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000566	0.00293	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000565	0.00293	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000565	0.00293	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000564	0.00292	CcSEcCtD
Lisdexamfetamine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000562	0.00291	CcSEcCtD
Lisdexamfetamine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000562	0.00291	CcSEcCtD
Lisdexamfetamine—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00056	0.0029	CcSEcCtD
Lisdexamfetamine—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00056	0.0029	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000558	0.00289	CcSEcCtD
Lisdexamfetamine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000555	0.00288	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000553	0.00287	CcSEcCtD
Lisdexamfetamine—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000548	0.00284	CcSEcCtD
Lisdexamfetamine—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000546	0.00283	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000544	0.00282	CcSEcCtD
Lisdexamfetamine—Amphetamine—SLC6A4—chronic obstructive pulmonary disease	0.000543	0.132	CrCbGaD
Lisdexamfetamine—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000533	0.00277	CcSEcCtD
Lisdexamfetamine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000531	0.00275	CcSEcCtD
Lisdexamfetamine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000528	0.00274	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000526	0.00273	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000526	0.00273	CcSEcCtD
Lisdexamfetamine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000521	0.0027	CcSEcCtD
Lisdexamfetamine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000521	0.0027	CcSEcCtD
Lisdexamfetamine—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000519	0.00269	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000518	0.00268	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000514	0.00266	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000514	0.00266	CcSEcCtD
Lisdexamfetamine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000512	0.00265	CcSEcCtD
Lisdexamfetamine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000512	0.00265	CcSEcCtD
Lisdexamfetamine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.00051	0.00265	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000507	0.00263	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000507	0.00263	CcSEcCtD
Lisdexamfetamine—Methamphetamine—SLC6A4—chronic obstructive pulmonary disease	0.000503	0.122	CrCbGaD
Lisdexamfetamine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000502	0.0026	CcSEcCtD
Lisdexamfetamine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000501	0.00259	CcSEcCtD
Lisdexamfetamine—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000499	0.00259	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000497	0.00258	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000497	0.00258	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000497	0.00257	CcSEcCtD
Lisdexamfetamine—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000497	0.00257	CcSEcCtD
Lisdexamfetamine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000497	0.00257	CcSEcCtD
Lisdexamfetamine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000493	0.00255	CcSEcCtD
Lisdexamfetamine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000493	0.00255	CcSEcCtD
Lisdexamfetamine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000492	0.00255	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000487	0.00253	CcSEcCtD
Lisdexamfetamine—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000487	0.00252	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000485	0.00251	CcSEcCtD
Lisdexamfetamine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000484	0.00251	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000482	0.0025	CcSEcCtD
Lisdexamfetamine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000481	0.00249	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.00048	0.00249	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000479	0.00248	CcSEcCtD
Lisdexamfetamine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000477	0.00247	CcSEcCtD
Lisdexamfetamine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000477	0.00247	CcSEcCtD
Lisdexamfetamine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000474	0.00246	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000473	0.00245	CcSEcCtD
Lisdexamfetamine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000472	0.00245	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00047	0.00243	CcSEcCtD
Lisdexamfetamine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000469	0.00243	CcSEcCtD
Lisdexamfetamine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000465	0.00241	CcSEcCtD
Lisdexamfetamine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000458	0.00237	CcSEcCtD
Lisdexamfetamine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000458	0.00237	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000455	0.00236	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000455	0.00236	CcSEcCtD
Lisdexamfetamine—SLC18A2—Synaptic Vesicle Pathway—SLC6A4—chronic obstructive pulmonary disease	0.000454	0.0349	CbGpPWpGaD
Lisdexamfetamine—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.000454	0.00235	CcSEcCtD
Lisdexamfetamine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000454	0.00235	CcSEcCtD
Lisdexamfetamine—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.000451	0.00234	CcSEcCtD
Lisdexamfetamine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00045	0.00233	CcSEcCtD
Lisdexamfetamine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00045	0.00233	CcSEcCtD
Lisdexamfetamine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00045	0.00233	CcSEcCtD
Lisdexamfetamine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000448	0.00232	CcSEcCtD
Lisdexamfetamine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000447	0.00232	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000446	0.00231	CcSEcCtD
Lisdexamfetamine—SLC6A2—Monoamine Transport—SLC6A4—chronic obstructive pulmonary disease	0.000444	0.0341	CbGpPWpGaD
Lisdexamfetamine—Irritability—Prednisone—chronic obstructive pulmonary disease	0.00044	0.00228	CcSEcCtD
Lisdexamfetamine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000432	0.00224	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.00043	0.00223	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000424	0.0022	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000424	0.0022	CcSEcCtD
Lisdexamfetamine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000424	0.0022	CcSEcCtD
Lisdexamfetamine—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000423	0.00219	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000416	0.00215	CcSEcCtD
Lisdexamfetamine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000413	0.00214	CcSEcCtD
Lisdexamfetamine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000413	0.00214	CcSEcCtD
Lisdexamfetamine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000405	0.0021	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000401	0.00208	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000394	0.00204	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000394	0.00204	CcSEcCtD
Lisdexamfetamine—SLC6A3—Monoamine Transport—SLC6A4—chronic obstructive pulmonary disease	0.000393	0.0302	CbGpPWpGaD
Lisdexamfetamine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.00039	0.00202	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000386	0.002	CcSEcCtD
Lisdexamfetamine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000381	0.00197	CcSEcCtD
Lisdexamfetamine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000381	0.00197	CcSEcCtD
Lisdexamfetamine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000373	0.00193	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000372	0.00193	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000367	0.0019	CcSEcCtD
Lisdexamfetamine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000366	0.0019	CcSEcCtD
Lisdexamfetamine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000366	0.0019	CcSEcCtD
Lisdexamfetamine—Rash—Formoterol—chronic obstructive pulmonary disease	0.000363	0.00188	CcSEcCtD
Lisdexamfetamine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000363	0.00188	CcSEcCtD
Lisdexamfetamine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000363	0.00188	CcSEcCtD
Lisdexamfetamine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000363	0.00188	CcSEcCtD
Lisdexamfetamine—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000363	0.00188	CcSEcCtD
Lisdexamfetamine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000361	0.00187	CcSEcCtD
Lisdexamfetamine—Headache—Formoterol—chronic obstructive pulmonary disease	0.000361	0.00187	CcSEcCtD
Lisdexamfetamine—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000361	0.00187	CcSEcCtD
Lisdexamfetamine—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.00036	0.00187	CcSEcCtD
Lisdexamfetamine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00036	0.00186	CcSEcCtD
Lisdexamfetamine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000359	0.00186	CcSEcCtD
Lisdexamfetamine—Rash—Montelukast—chronic obstructive pulmonary disease	0.000356	0.00184	CcSEcCtD
Lisdexamfetamine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000355	0.00184	CcSEcCtD
Lisdexamfetamine—Depression—Prednisone—chronic obstructive pulmonary disease	0.000354	0.00184	CcSEcCtD
Lisdexamfetamine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000354	0.00183	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.00035	0.00182	CcSEcCtD
Lisdexamfetamine—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000349	0.00181	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000348	0.00181	CcSEcCtD
Lisdexamfetamine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000346	0.00179	CcSEcCtD
Lisdexamfetamine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000343	0.00178	CcSEcCtD
Lisdexamfetamine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000343	0.00178	CcSEcCtD
Lisdexamfetamine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000342	0.00177	CcSEcCtD
Lisdexamfetamine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000342	0.00177	CcSEcCtD
Lisdexamfetamine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000341	0.00177	CcSEcCtD
Lisdexamfetamine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000335	0.00174	CcSEcCtD
Lisdexamfetamine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000331	0.00172	CcSEcCtD
Lisdexamfetamine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.00033	0.00171	CcSEcCtD
Lisdexamfetamine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000323	0.00167	CcSEcCtD
Lisdexamfetamine—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000318	0.00165	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000312	0.00162	CcSEcCtD
Lisdexamfetamine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000305	0.00158	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000302	0.00156	CcSEcCtD
Lisdexamfetamine—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000298	0.00155	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000288	0.00149	CcSEcCtD
Lisdexamfetamine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000282	0.00146	CcSEcCtD
Lisdexamfetamine—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.00028	0.00145	CcSEcCtD
Lisdexamfetamine—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000278	0.00144	CcSEcCtD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	0.000262	0.0201	CbGpPWpGaD
Lisdexamfetamine—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000262	0.00136	CcSEcCtD
Lisdexamfetamine—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000255	0.00132	CcSEcCtD
Lisdexamfetamine—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000254	0.00132	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—CHRNA5—chronic obstructive pulmonary disease	0.000251	0.0193	CbGpPWpGaD
Lisdexamfetamine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000248	0.00128	CcSEcCtD
Lisdexamfetamine—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000241	0.00125	CcSEcCtD
Lisdexamfetamine—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.00024	0.00124	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000238	0.0183	CbGpPWpGaD
Lisdexamfetamine—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000236	0.00122	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000235	0.00122	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.00023	0.00119	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000227	0.00118	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000222	0.00115	CcSEcCtD
Lisdexamfetamine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000221	0.00115	CcSEcCtD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.00022	0.0169	CbGpPWpGaD
Lisdexamfetamine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.00022	0.00114	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000219	0.00114	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.000218	0.0167	CbGpPWpGaD
Lisdexamfetamine—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000216	0.00112	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000212	0.0163	CbGpPWpGaD
Lisdexamfetamine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000206	0.00107	CcSEcCtD
Lisdexamfetamine—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000205	0.00106	CcSEcCtD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000205	0.0158	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—CHRNA3—chronic obstructive pulmonary disease	0.000205	0.0157	CbGpPWpGaD
Lisdexamfetamine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.0002	0.00103	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000197	0.00102	CcSEcCtD
Lisdexamfetamine—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000197	0.00102	CcSEcCtD
Lisdexamfetamine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000197	0.00102	CcSEcCtD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—TGFB1—chronic obstructive pulmonary disease	0.000196	0.0151	CbGpPWpGaD
Lisdexamfetamine—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000195	0.00101	CcSEcCtD
Lisdexamfetamine—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000195	0.00101	CcSEcCtD
Lisdexamfetamine—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000194	0.001	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.000193	0.0148	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000193	0.0148	CbGpPWpGaD
Lisdexamfetamine—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000185	0.000961	CcSEcCtD
Lisdexamfetamine—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.00018	0.000934	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000179	0.000929	CcSEcCtD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000172	0.0132	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—ADIPOQ—chronic obstructive pulmonary disease	0.00017	0.0131	CbGpPWpGaD
Lisdexamfetamine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000167	0.000866	CcSEcCtD
Lisdexamfetamine—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000163	0.000843	CcSEcCtD
Lisdexamfetamine—SLC6A2—Monoamine Transport—IL1B—chronic obstructive pulmonary disease	0.000161	0.0124	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.00016	0.0123	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.000157	0.0121	CbGpPWpGaD
Lisdexamfetamine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000155	0.000804	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000155	0.0119	CbGpPWpGaD
Lisdexamfetamine—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.00015	0.000777	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA5—chronic obstructive pulmonary disease	0.00015	0.0115	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000144	0.000747	CcSEcCtD
Lisdexamfetamine—SLC6A3—Monoamine Transport—IL1B—chronic obstructive pulmonary disease	0.000143	0.011	CbGpPWpGaD
Lisdexamfetamine—Rash—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000741	CcSEcCtD
Lisdexamfetamine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000143	0.00074	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000143	0.011	CbGpPWpGaD
Lisdexamfetamine—Headache—Prednisone—chronic obstructive pulmonary disease	0.000142	0.000736	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000142	0.0109	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000142	0.0109	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000137	0.0106	CbGpPWpGaD
Lisdexamfetamine—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000698	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000134	0.0103	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000132	0.0101	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000126	0.00971	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000126	0.00965	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA3—chronic obstructive pulmonary disease	0.000122	0.00938	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000119	0.00915	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—TNF—chronic obstructive pulmonary disease	0.000117	0.009	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—TGFB1—chronic obstructive pulmonary disease	0.000117	0.00899	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000117	0.00897	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000115	0.00882	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—LEP—chronic obstructive pulmonary disease	0.000106	0.00812	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—TNF—chronic obstructive pulmonary disease	0.000104	0.00797	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	9.94e-05	0.00764	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	9.81e-05	0.00753	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	9.36e-05	0.00719	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	9.14e-05	0.00702	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	8.81e-05	0.00677	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	8.69e-05	0.00667	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	8.09e-05	0.00622	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	8.07e-05	0.0062	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	7.85e-05	0.00603	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—CXCL8—chronic obstructive pulmonary disease	7.46e-05	0.00573	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	6.91e-05	0.00531	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP9—chronic obstructive pulmonary disease	6.74e-05	0.00518	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	5.85e-05	0.00449	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	5.51e-05	0.00424	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—EGFR—chronic obstructive pulmonary disease	5.45e-05	0.00419	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	5.26e-05	0.00404	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	5.23e-05	0.00402	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	5.12e-05	0.00393	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	5.06e-05	0.00389	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	4.67e-05	0.00359	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	4.58e-05	0.00352	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	4.34e-05	0.00333	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	4.31e-05	0.00331	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TP53—chronic obstructive pulmonary disease	4.31e-05	0.00331	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	3.96e-05	0.00304	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	3.87e-05	0.00298	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	3.72e-05	0.00286	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	3.71e-05	0.00285	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	3.69e-05	0.00284	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	3.39e-05	0.0026	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	3.35e-05	0.00257	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	3.3e-05	0.00254	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	3.3e-05	0.00253	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	3.29e-05	0.00253	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	3.14e-05	0.00241	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	2.97e-05	0.00229	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	2.95e-05	0.00227	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.8e-05	0.00215	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.78e-05	0.00214	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	2.7e-05	0.00208	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	2.61e-05	0.00201	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	2.58e-05	0.00198	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.09e-05	0.00161	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	2.07e-05	0.00159	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.98e-05	0.00152	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.89e-05	0.00145	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.87e-05	0.00143	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.69e-05	0.0013	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.67e-05	0.00128	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.67e-05	0.00128	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.6e-05	0.00123	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.59e-05	0.00123	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.59e-05	0.00122	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.51e-05	0.00116	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.46e-05	0.00112	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.32e-05	0.00102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.17e-05	0.000896	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.08e-05	0.000833	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1e-05	0.000769	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	9.01e-06	0.000692	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	8.95e-06	0.000687	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	8.18e-06	0.000629	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	8.13e-06	0.000625	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	7.83e-06	0.000601	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	7.28e-06	0.000559	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	5.98e-06	0.00046	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.71e-06	0.000439	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.45e-06	0.000419	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.83e-06	0.000371	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.6e-06	0.000353	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.37e-06	0.000336	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.93e-06	0.000302	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.6e-06	0.000277	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.53e-06	0.000271	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.97e-06	0.000228	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.72e-06	0.000209	CbGpPWpGaD
